ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Not Just an "Ill Person" - Ways to expand your identity when you're chronically ill

Is Poor Sleep Pummeling the Immune System in ME/CFS and Fibromyalgia? A Vicious Circle Examined

Is Chronic Fatigue Real?

Taking a Moment

Staying Connected with Friends While Ill

VIDEO: Illness and Isolation

Glial Cell Inhibitors: The Next Sleep Drugs for Fibromyalgia and Chronic Fatigue Syndrome (ME/CFS)?

Inflammation correlates with symptoms in chronic fatigue syndrome

Recognizing the Needs of Pain Patients in Substance Use Policy

Call Out the Imbalance in Current Policy Making for Pain Management and Prescription Opioid Use

 
Print Page
Email Article

New York Times Opinion Piece Slams PACE Trial and Lancet

  [ 13 votes ]   [ Discuss This Article ]
By Cort Johnson • www.ProHealth.com • March 29, 2017


New York Times Opinion Piece Slams PACE Trial and Lancet
It's not often that you see the words "chronic fatigue syndrome" on the New York Times front page but there they were. The title of Julie Rehmeyer and David Tuller's op-ed piece on the PACE trial, "Getting It Wrong on Chronic Fatigue Syndrome", was highlighted there in bold for about half a day.

It's not easy to get on the editorial page of the most influential newspaper in the West. Hundreds send submissions in but only a select few get published.
 
I know - I tried. I thought I had a drop-dead, sure to be published article. Submitted when the film Unbroken came out, it was timely, had a hot title, I thought ("Why Laura Hillenbrand Will Never Get Well"), included a great story (Laura's) and provided some juicy facts about the NIH's decades long neglect of over a million Americans. It was a sure winner, I thought…I never heard back.

So who does get on the opinion pages of the second most read newspaper in the U.S.? A look at the recent op-eds found that authorsprofessors, politicians and sometimes world renowned figures populate the NY Times Opinion pages. The op-ed section of the New York Times is clearly where the elite go to communicate their thoughts.

The reason I checked is that I don't think Julie Rehmeyer and David Tuller, as good as they are, got into the NY Times opinion pages on the strength of their credentials. They got in there on the strength of a story of scientific malfeasance which is still playing out. It's important to note here that the New York Times applies the same rigorous fact-checking they do in their regular articles to the op-ed pages. Nobody gets into the op-ed pages spouting false facts. The presence of the piece in the New York Times tells the world that Rehmeyer's and Tuller's facts check out.

The Contortionists
 
The article revealed the remarkable contortions the PACE trial authors put their data through to ensure that the biggest study ever in chronic fatigue syndrome delivered the goods.

The whole PACE trial saga constitutes a death of innocence for ME/CFS patients. It's not as if people with ME/CFS trusted a medical profession which often told them their disease was all in their head. Many of us, me included, believed that if a weight of overwhelming evidence was presented the powers that be would surely listen. That hasn't proven to be the case at least at The Lancet and the other journals.

CBT and GET are still listed on many major medical websites as the go-to therapies for ME/CFS; therapies which some sites still maintain many help patients recover. That's in direct contrast to the more recent Institute of Medicine report's finding that even minimal activity can lead to exhaustion, cognitive problems, muscle pain, etc. is ignored. Such is the legacy of PACE.

What's Next?

What happens when the English speaking world's most influential newspaper smacks up against the one of the English speaking world's most influential science journals? We'll see. Richard Horton, the editor of The Lancet, has done everything he can to delay, obfuscate or otherwise impede the progress of any independent analysis of the PACE trial.

Horton defended keeping the study because the environment on social media regarding the PACE trial is not conducive to scientific discourse. Horton, who, ironically, has called for more transparency in the academic world, has fed that fire in numerous ways. He said he would publish a letter from concerned researchers, then not only refused to publish the letter once it was provided but never responded to it. Horton actually turned to the PACE trial authors to help him decide whether to publish the letter.
It took a legal fight and a court order to get the original PACE data released. As to Horton's and the PACE author's concerns about frenzied patients, the court found that patients' concerns were real, was unable to find evidence of unbalanced ME/CFS patients, and rebuked the defendants' behavior as unprofessional.

Horton has chosen to ignore the investigator's own re-analysis of their data which revealed that far, far fewer of the ME/CFS patients in the trial "improved" using the original criteria, and that many of those would have improved without using CBT or GET. Horton apparently doesn't find it suspicious that every change the study authors made in the PACE trial increased their ability to say it was effective.

Horton is hanging in there while others are tearing his reputation to shreds. Apparently it hasn't been enough. If ME/CFS weren't such a niche topic it's hard to imagine he'd still be editor of the Lancet.

The situation isn't much better with Psychological Medicine - the journal which produced the PACE recovery findings. Recently, over 100 researchers, doctors and organizations sent an open letter to Psychological Medicine asking it to retract the study which stated that 22% of the ME/CFS patients recovered and that CBT and GET provided "the best chance for a cure".
 
The letter noted that the PACE authors relaxed, apparently without oversight, each of the four criteria needed for "recovery" after the study had begun. Two of the four criteria were so lax that 13% of the patients could have been counted as both ill with ME/CFS and recovered at the same time. When a re-analysis of the data was done using the original criteria neither CBT nor GET significantly increased an ME/CFS patient's chance of recovery.

Psychological Medicine is twisting itself into a pretzel in its attempts to have it both ways. It's said that it's unwilling to retract the original study, but that it's "open" (whatever that means) to publishing the re-analysis of the PACE trial which, of course, revealed the trial was bogus.

Given Lancet's and Psychological Medicine's intransigence, thus far, I wouldn't hold my breath waiting for that to happen. The latest New York Times piece will add a bit more fuel to the PACE fire. Meanwhile, the scientific community will probably have to find more ways to apply pressure for this this effort to succeed.

Julie Rehmeyer spoke of how much the opinion piece meant to her in a Facebook post. Rehmeyer, through her articles, has played a major role in exposing the PACE trials flaws. Since the PACE trial came out she's gone from being disabled to healthy, and a book "Through the Shadowlands: A Science Writer's Odyssey into an Illness Science Doesn't Understand" describing her surprising journey to health is available for pre-order. For her, as for many others, the PACE trial has become personal:
Please share "Getting It Wrong on Chronic Fatigue Syndrome".

ProHealth is pleased to share information from Cort Johnson.  Cort has had ME/CFS for over 30 years. The founder of Phoenix Rising and Health Rising, he has contributed hundreds of blogs on chronic fatigue syndrome, fibromyalgia and their allied disorders over the past 10 years. Find more of Cort's and other bloggers' work at Health Rising.



Post a Comment

Featured Products From the ProHealth Store
Ultra ATP+, Double Strength MitoQ® Hydroxocobalamin Extreme™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 Your Brain Needs for Detox & Sharpness
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria

Natural Remedies

Looking for Energy? Turn to Plants. Looking for Energy? Turn to Plants.
Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed
Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency
Safely Burn Away Body Fat Safely Burn Away Body Fat

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map